Набор от данни: Актуализация на регистрите на НСЦРЛП към 02.09.2016 г.
Приложение 3 на ПЛС актуализация 02.09.2016
Уникален идентификатор: 36e37264-bdad-492e-bf9c-113503474755
здравеопазване
лекарства
реимбурсиране
Текуща версия: 1
Показвана версия: 1
Формат: CSV
|
ПОЗИТИВЕН ЛЕКАРСТВЕН СПИСЪК |
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Актуализация към 02.09.2016 | |||||||||||||||||||||
| ПРИЛОЖЕНИЕ 3 | |||||||||||||||||||||
| Лекарствени продукти, предназначени за лечение на СПИН, на инфекциозни заболявания, на заболявания извън обхвата на ЗЗО, заплащани по реда на чл. 82, ал. 1, т. 8 от Закона за здравето, както и ваксини за задължителни имунизации и реимунизации, ваксини по специални показания и при извънредни обстоятелства, специфични серуми, имуноглобулини, определени с наредбата по чл. 58, ал. 2 от Закона за здравето | |||||||||||||||||||||
| Анатомо-терапевтичен код /АТС-код/ | Международно непатентно наименование /INN/ | Наименование на лекарствения продукт | Лекарствена форма | Количество на активното лекарствено вещество | Окончателна опаковкат | Притежател на разрешението за употреба | DDD/Терапевтичен курс | Цена по чл. 261a, ал.1 от ЗЛПХМ | Референтна стойност за DDD/ Терапевтичен курс | Стойност за опаковка, изчислена на база референтна стойност | Ниво на заплащане (%) | Ограничения в начина на предписване при различни индикации | МКБ | Допълнителна информация | Статус | Идентификатор на ЛП | |||||
| №/дата на решението | Дата на настъпили промени в обстоятелствата | Дата на настъпили промени в обстоятелствата във връзка с ПМС 196/2012 г., ДВ, бр. 68 от 04.09.2012 г. | Дата на настъпили промени в обстоятелствата във връзка с &8 на НУПРЗРРЦЛП за привеждане в съответствие с чл. 1, ал. 3 от Наредба №42 на МЗ | ||||||||||||||||||
| J04AB02 | Rifampicin | ||||||||||||||||||||
| J04AB02 | Rifampicin | TUBOCIN | Capsule, hard | 300 | mg | 100 | Актавис EАД, България | 600 | mg | 33.91 | 0.6782 | 33.91 | 100% | A15,A15.0,A15.1,A15.2,A15.3,A15.5,A15.6,A15.7,A15.8,A15.9,A16.0,A16.1,A16.2,A16.3,A16.4,A16.5,A16.7,A16.8,A16.9,A17.0,A17.1,A17.8,A17.9,A18.0,A18.1,A18.2,A18.3,A18.4,A18.5,A18.6,A18.7,A18.8,A19.0,A19.1,A19.2,A19.8,A19.9,B90.0,B90.1,B90.2,B90.8,B90.9 | HCР-410/03.07.2013 | 08.09.2012 | Активен | 1956 | |||
| J04AC01 | Isoniazid | ||||||||||||||||||||
| J04AC01 | Isoniazid | RIMICID | Solution for injection | 25 mg/ml - 2 ml | mg | 10 | Софарма АД, България | 300 | mg | 11.56 | 6.93599 | 11.56 | 100% | A15,A15.0,A15.1,A15.2,A15.3,A15.5,A15.6,A15.7,A15.8,A15.9,A16.0,A16.1,A16.2,A16.3,A16.4,A16.5,A16.7,A16.8,A16.9,A17.0,A17.1,A17.8,A17.9,A18.0,A18.1,A18.2,A18.3,A18.4,A18.5,A18.6,A18.7,A18.8,A19.0,A19.1,A19.2,A19.8,A19.9,B90.0,B90.1,B90.2,B90.8,B90.9 | 08.09.2012 | Активен | 146 | ||||
| J04AC01 | Isoniazid | ||||||||||||||||||||
| J04AC01 | Isoniazid | ISONID | Tablet | 100 | mg | 100 | Фармацевтични заводи Милве АД, България | 300 | mg | 2.46 | 0.0738 | 2.46 | 100% | A15,A15.0,A15.1,A15.2,A15.3,A15.5,A15.6,A15.7,A15.8,A15.9,A16.0,A16.1,A16.2,A16.3,A16.4,A16.5,A16.7,A16.8,A16.9,A17.0,A17.1,A17.8,A17.9,A18.0,A18.1,A18.2,A18.3,A18.4,A18.5,A18.6,A18.7,A18.8,A19.0,A19.1,A19.2,A19.8,A19.9,B90.0,B90.1,B90.2,B90.8,B90.9 | 08.09.2012 | Активен | 281 | ||||
| J04AC01 | Isoniazid | RIMICID | Tablet | 100 | mg | 100 | Софарма АД, България | 300 | mg | 3.55 | 0.0738 | 2.46 | 100% | A15,A15.0,A15.1,A15.2,A15.3,A15.5,A15.6,A15.7,A15.8,A15.9,A16.0,A16.1,A16.2,A16.3,A16.4,A16.5,A16.7,A16.8,A16.9,A17.0,A17.1,A17.8,A17.9,A18.0,A18.1,A18.2,A18.3,A18.4,A18.5,A18.6,A18.7,A18.8,A19.0,A19.1,A19.2,A19.8,A19.9,B90.0,B90.1,B90.2,B90.8,B90.9 | 08.09.2012 | Активен | 39 | ||||
| J04AK01 | Pyrazinamide | ||||||||||||||||||||
| J04AK01 | Pyrazinamide | PYRAZINAMIDE KRKA | Tablet | 500 | mg | 100 | KRKA, d.d., Словения | 1500 | mg | 19.57 | 0.58716 | 19.57 | 100% | A15,A15.0,A15.1,A15.2,A15.3,A15.5,A15.6,A15.7,A15.8,A15.9,A16.0,A16.1,A16.2,A16.3,A16.4,A16.5,A16.7,A16.8,A16.9,A17.0,A17.1,A17.8,A17.9,A18.0,A18.1,A18.2,A18.3,A18.4,A18.5,A18.6,A18.7,A18.8,A19.0,A19.1,A19.2,A19.8,A19.9,B90.0,B90.1,B90.2,B90.8,B90.9 | № 174/ 31.05.2011; HCР-312/03.07.2013; НСР-7070/09.09.2015 | 02.10.2015 | 08.09.2012 | Активен | 1954 | ||
| J04AK02 | Ethambutol | ||||||||||||||||||||
| J04AK02 | Ethambutol | ETHAMBUTOL-MILVE | Tablet | 250 | mg | 50 | Фармацевтични заводи Милве АД, България | 1200 | mg | 4.34 | 0.41664 | 4.34 | 100% | A15,A15.0,A15.1,A15.2,A15.3,A15.5,A15.6,A15.7,A15.8,A15.9,A16.0,A16.1,A16.2,A16.3,A16.4,A16.5,A16.7,A16.8,A16.9,A17.0,A17.1,A17.8,A17.9,A18.0,A18.1,A18.2,A18.3,A18.4,A18.5,A18.6,A18.7,A18.8,A19.0,A19.1,A19.2,A19.8,A19.9,B90.0,B90.1,B90.2,B90.8,B90.9 | № 138/ 24.01.2011 | 08.09.2012 | Активен | 282 | |||
| J04AK02 | Ethambutol | ETHAMBUTOL SOPHARMA 250 MG | Tablet | 250 | mg | 50 | Софарма АД, България | 1200 | mg | 5.54 | 0.41664 | 4.34 | 100% | A15,A15.0,A15.1,A15.2,A15.3,A15.5,A15.6,A15.7,A15.8,A15.9,A16.0,A16.1,A16.2,A16.3,A16.4,A16.5,A16.7,A16.8,A16.9,A17.0,A17.1,A17.8,A17.9,A18.0,A18.1,A18.2,A18.3,A18.4,A18.5,A18.6,A18.7,A18.8,A19.0,A19.1,A19.2,A19.8,A19.9,B90.0,B90.1,B90.2,B90.8,B90.9 | № 138/ 24.01.2011 | 08.09.2012 | Активен | 155 | |||
| J04AK05 | Bedaquiline | ||||||||||||||||||||
| J04AK05 | Bedaquiline | Sirturo | Tablet | 100 | mg | 188 | Janssen-Cilag International N.V., Белгия | 86 | mg | 26708.42 | 122.17941 | 26708.42 | 100% | по изключение за други видове туберкулоза след решение на Експертната комисия за мониторинг на лечението на пациенти с MDR/XDR-TB | A15.1 | НСР-7816/28.12.2015 | Активен | 4164 | |||
| J05AE01 | Saquinavir | ||||||||||||||||||||
| J05AE01 | Saquinavir | INVIRASE | Film‐coated tablet | 500 | mg | 120 | Roche Registration Limited, Обединено Кралство | 1800 | mg | 456.8 | 13.70537 | 456.8 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | № 24/31.07.2009. КЦРР-677/30.05.2012 г.; НСР-4283/05.08.2014; НСР-6078/23.04.2015; НСР-9706/07.07.2016 | 42584 | 08.09.2012 | Активен | 3837 | ||
| J05AE03 | Ritonavir | ||||||||||||||||||||
| J05AE03 | Ritonavir | NORVIR | Capsule, soft | 100 | mg | 336 | Abbott Laboratories Limited, Обединено Кралство | 1200 | mg | 403.85 | 14.42321 | 403.85 | 100% | B20,B24,Z21 | КЦРР-559/04.05.2012 г.; КЦРР-948/16.07.2012 | 20.07.2012 | 08.09.2012 | Заличен | 1207 | ||
| J05AE03 | Ritonavir | NORVIR | Film‐coated tablet | 100 | mg | 30 | AbbVie Ltd, Обединено Кралство | 1200 | mg | 46.93 | 18.772 | 46.93 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | № 197/ 19.09.2011; НСР-496/11.07.2013;НСР-1647/11.11.2013; НСР-5632/12.02.2015; НСР-7127/24.09.2015; НСР-9390/01.06.2016 | 02.07.2016 | 08.09.2012 | Активен | 3579 | ||
| J05AE07 | Fosamprenavir | ||||||||||||||||||||
| J05AE07 | Fosamprenavir | TELZIR | Film‐coated tablet | 700 | mg | 60 | Viiv Healthcare UK Ltd.,, Обединено Кралство | 1400 | mg | 635.95 | 21.19833 | 635.95 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | № 122/ 09.12.2010; КЦРР-2459/27.02.2013 г.; НСР-1912/27.11.2013; НСР-4322/05.08.2014; НСР-6086/23.04.2015; НСР-7781/28.12.2015 | 02.02.2016 | 08.09.2012 | Активен | 3825 | ||
| J05AE08 | Atazanavir | ||||||||||||||||||||
| J05AE08 | Atazanavir | REYATAZ | Capsule, hard | 150 | mg | 60 | Bristol-Myers Squibb Pharma EEIG, Обединено Кралство | 1 | mg | 792.07 | 0.08801 | 792.07 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | № 16/24.06.2009 г.; КЦРР-806/15.06.2012 г.; ; НСР-107/07.06.2013.;НСР-3056/21.03.2014 и КП-14/17.02.2015.; НСР-4658/25.09.2014 и КП-95/06.04.2015 | 02.05.2015 | 08.09.2012 | Активен | 3755 | ||
| J05AE09 | Tipranvir | ||||||||||||||||||||
| J05AE09 | Tipranvir | Aptivus | Capsule, soft | 250 mg | mg | 120 | Boehringer Ingelheim International GmbH, Германия | 1 | mg | 1631.42 | 0.05438 | 1631.42 | 100% | B20,B24,Z21 | КЦРР-2933/20.03.2013 | 08.09.2012 | 16.01.2014 | Заличен | 280 | ||
| J05AE10 | Darunavir | ||||||||||||||||||||
| J05AE10 | Darunavir | Prezista | Film‐coated tablet | 300 | mg | 120 | Janssen-Cilag International N.V., Белгия | 1200 | mg | 1523.12 | 50.77067 | 1523.12 | 100% | B20,B24,Z21 | КЦРР-931/04.07.2012 | 08.09.2012 | Заличен | 407 | |||
| J05AE10 | Darunavir | PREZISTA | Film‐coated tablet | 400 | mg | 60 | Janssen-Cilag International N.V., Белгия | 1200 | mg | 834.65 | 41.34467 | 826.89 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | № 151/ 14.03.2011; НСР-1618/01.11.2013; НСР-1888/27.11.2013; НСР-3989/30.06.2014; НСР-5751/26.02.2015 | 42584 | 08.09.2012 | Активен | 3628 | ||
| J05AE10 | Darunavir | PREZISTA | Film‐coated tablet | 600 | mg | 60 | Janssen-Cilag International N.V., Белгия | 1200 | mg | 1240.34 | 41.34467 | 1240.34 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | №100/ 23.08.2010; КЦРР-1165/08.08.2012 г.; НСР-1731/21.11.2013; НСР-4998/05.11.2014; НСР-9721/07.07.2016 | 42584 | 08.09.2012 | 16.01.2014 | Активен | 3333 | |
| J05AE10 | Darunavir | PREZISTA | Film‐coated tablet | 800 | mg | 30 | Janssen-Cilag International N.V., Белгия | 1200 | mg | 834.95 | 41.34467 | 826.89 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | НСР-6572/24.06.2015; НСР-8441/07.03.2016 | 42584 | Активен | 4025 | |||
| J05AF01 | Zidovudine | ||||||||||||||||||||
| J05AF01 | Zidovudine | RETROVIR | Capsule, hard | 100 | mg | 100 | Viiv Healthcare UK Ltd.,, Обединено Кралство | 600 | mg | 185.75 | 11.145 | 185.75 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | № 120/ 09.12.2010; № 189/ 22.08.2011 | 08.09.2012 | 16.01.2014 | Активен | 970 | ||
| J05AF01 | Zidovudine | ||||||||||||||||||||
| J05AF01 | Zidovudine | RETROVIR | Oral solution | 10mg/ml -200ml | mg | 1 | Viiv Healthcare UK Ltd.,, Обединено Кралство | 600 | mg | 21.89 | 6.57357 | 21.89 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | НСР-1077/02.09.2013; НСР-3390/29.04.2014; НСР-5312/ 18.12.2014; НСР-8327/26.02.2016 | 02.04.2016 | Активен | 3482 | |||
| J05AF02 | Didanosine | ||||||||||||||||||||
| J05AF02 | Didanosine | VIDEX EC | Gastro‐resistant capsule, hard | 400 | mg | 30 | Bristol-Myers Squibb, Унгария | 1 | mg | 290.12 | 0.02418 | 290.12 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | КЦРР-1000/23.07.2012; НСР-9745/14.07.2016 | 42584 | 08.09.2012 | Заличен | 1291 | ||
| J05AF02 | Didanosine | VIDEX EC | Gastro‐resistant capsule, hard | 250 | mg | 30 | Bristol-Myers Squibb, Унгария | 1 | mg | 181.33 | 0.02418 | 181.33 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | КЦРР-1000/23.07.2012; НСР-9746/14.07.2016 | 42584 | 08.09.2012 | Заличен | 1290 | ||
| J05AF04 | Stavudine | ||||||||||||||||||||
| J05AF04 | Stavudine | ZERIT | Capsule, hard | 40 | mg | 56 | Bristol-Myers Squibb Pharma EEIG, Обединено Кралство | 80 | mg | 270.84 | 9.67286 | 270.84 | 100% | B20,B24,Z21 | КЦРР-687/30.05.2012 г.; КЦРР-1533/25.10.2012 | 20.11.2012 | 08.09.2012 | Заличен | 1226 | ||
| J05AF04 | Stavudine | ZERIT | Capsule, hard | 30 | mg | 56 | Bristol-Myers Squibb Pharma EEIG, Обединено Кралство | 80 | mg | 262.1 | 9.67286 | 203.13 | 100% | B20,B24,Z21 | КЦРР-687/30.05.2012 г.; КЦРР-1533/25.10.2012 | 20.11.2012 | 08.09.2012 | Заличен | 1225 | ||
| J05AF05 | Lamivudine | ||||||||||||||||||||
| J05AF05 | Lamivudine | EPIVIR | Film‐coated tablet | 150 | mg | 60 | Viiv Healthcare UK Ltd.,, Обединено Кралство | 300 | mg | 153.14 | 5.10467 | 153.14 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | № 120/ 09.12.2010; КЦРР-2793/20.03.2013.; и НСР-360/03.07.2013; НСР-5741/26.02.2015 | 16.03.2015 | 08.09.2012 | 16.01.2014 | Активен | 3632 | |
| J05AF05 | Lamivudine | ||||||||||||||||||||
| J05AF05 | Lamivudine | EPIVIR | Oral solution | 10mg/ml - 240ml | mg | 1 | Viiv Healthcare UK Ltd.,, Обединено Кралство | 300 | mg | 40.76 | 5.095 | 40.76 | 100% | съгл. РУ | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | НСР-1078/02.09.2013; НСР-4992/05.11.2014; НСР-9725/07.07.2016 | 42584 | Активен | 3338 | ||
| J05AF06 | Abacavir | ||||||||||||||||||||
| J05AF06 | Abacavir | ZIAGEN | Film‐coated tablet | 300 | mg | 60 | Viiv Healthcare UK Ltd.,, Обединено Кралство | 600 | mg | 429.35 | 14.31167 | 429.35 | 100% | B20.0,B20.9,B21.0,B21.3,B21.7,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | № 120/ 09.12.2010; № 255/ 04.11.2011; НСР-2721/06.02.2014 | 08.09.2012 | 16.01.2014 | Заличен | 971 | ||
| J05AF07 | Tenofovir disoproxil | ||||||||||||||||||||
| J05AF07 | Tenofovir disoproxil | Viread | Film‐coated tablet | 245 | mg | 30 | Gilead Sciences International Ltd., Обединено Кралство | 1 | mg | 578.57 | 0.07872 | 578.57 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | КЦРР-568/04.05.2012 г.; КЦРР-936/16.07.2012 г.; НСР-2191/20.12.2013; НСР-5914/27.03.2015.; НСР-7692/10.12.2015 | 02.01.2016 | 08.09.2012 | Активен | 3712 | ||
| J05AF09 | Emtricitabine | ||||||||||||||||||||
| J05AF09 | Emtricitabine | Emtriva | Capsules | 200 | mg | 30 | Gilead Sciences International Ltd., Обединено Кралство | 1 | mg | 305.72 | 0.05095 | 305.72 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | ; КП-61/12.04.2016 и НСР-5915/27.03.2015; корек. НСР-6070/21.04.2015; | 02.06.2016 | 08.09.2012 | 16.01.2014 | Активен | 2391 | |
| J05AG01 | Nevirapine | ||||||||||||||||||||
| J05AG01 | Nevirapine | NEVIRAPINE TEVA | Tablet | 200 | mg | 60 | Teva B.V., Нидерландия | 400 | mg | 170.62 | 5.68733 | 170.62 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | №100/ 23.08.2010; КЦРР-1061/26.07.2012 г.; НСР-1739/21.11.2013; НСР-7149/09.10.2015 | 02.11.2015 | 08.09.2012 | 16.01.2014 | Заличен | 2282 | |
| J05AG01 | Nevirapine | VIRAMUNE | Tablet | 200 | mg | 60 | Boehringer Ingelheim International GmbH, Германия | 400 | mg | 338.04 | 7.53067 | 225.92 | 100% | B20,B24,Z21 | КЦРР-1122/02.08.2012 г.; НСР-23/03.06.2013; HCР-500/11.07.2013 | 02.08.2013 | 08.09.2012 | 16.01.2014 | Заличен | 1864 | |
| J05AG03 | Efavirenz | ||||||||||||||||||||
| J05AG03 | Efavirenz | Stocrin | Film‐coated tablet | 200 | tabl. | 90 | Merck Sharp & Dohme Ltd., Обединено Кралство | 1 | mg | 132.54 | 0.00736 | 132.54 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | 08.09.2012 | Активен | 596 | ||||
| J05AG04 | Etravirine | ||||||||||||||||||||
| J05AG04 | Etravirine | INTELENCE | Tablet | 200 | mg | 60 | Janssen-Cilag International N.V., Белгия | 400 | mg | 856.36 | 28.03033 | 840.91 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | НСР-6573/24.06.2015 | Активен | 4026 | ||||
| J05AG04 | Etravirine | INTELENCE | Tablet | 100 | mg | 120 | Janssen-Cilag International N.V., Белгия | 400 | mg | 840.91 | 28.03033 | 840.91 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | №100/ 23.08.2010; КЦРР-1165/08.08.2012 г.; НСР-1731/21.11.2013; НСР-4997/05.11.2014 | 02.12.2014 | 08.09.2012 | 16.01.2014 | Активен | 3335 | |
| J05AG05 | Rilpivirine | ||||||||||||||||||||
| J05AG05 | Rilpivirine | EDURANT | Film‐coated tablet | 25 | mg | 30 | Janssen-Cilag International N.V., Белгия | 1 | mg | 521.8 | 0.69573 | 521.8 | 100% | съгл. РУ | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | НСР-1076/02.09.2013; НСР-4999/05.11.2014; НСР-7784/28.12.2015 | 02.02.2016 | Активен | 3344 | ||
| J05AH01 | Zanamivir | ||||||||||||||||||||
| J05AH01 | Zanamivir | RELENZA | Inhalation powder | 5 mg/dose x 4 doses x 5 rotadiskuses | mg | 1 | Glaxo Group Ltd., Обединено Кралство | 20 | mg | 25.25 | 5.05 | 25.25 | 100% | J10.0,J10.1,J10.8,J11.1 | КЦРР-2779/20.03.2013 г.; НСР-2539/24.01.2014; НСР-4817/13.10.2014 | 02.11.2014 | 08.09.2012 | Активен | 3262 | ||
| J05AH02 | Oseltamivir | ||||||||||||||||||||
| J05AH02 | Oseltamivir | Ebilfumin | Capsule, hard | 75 | mg | 10 | Actavis Group PTC ehf., Исландия | 150 | mg | 24.5 | 4.9 | 24.5 | 100% | J10.0,J10.1,J10.8,J11.1 | НСР-4273/05.08.2014 | Активен | 3072 | ||||
| J05AH02 | Oseltamivir | Tamiflu | Capsule, hard | 30 | mg | 10 | Roche Registration Limited, Обединено Кралство | 150 | mg | 16.42 | 4.9 | 9.8 | 100% | J10.0,J10.1,J10.8,J11.1 | №100/ 23.08.2010; КЦРР-2830/20.03.2013 г; НСР-2313/13.01.2014; НСР-6080/23.04.2015; НСР-9959/29.07.2016. | 16.05.2015; 02.09.2016. | 08.09.2012 | Активен | 3829 | ||
| J05AH02 | Oseltamivir | Tamiflu | Capsule, hard | 45 | mg | 10 | Roche Registration Limited, Обединено Кралство | 150 | mg | 30.85 | 4.9 | 14.7 | 100% | J10.0,J10.1,J10.8,J11.1 | №100/ 23.08.2010; НСР-4287/05.08.2014 | 08.09.2012 | Активен | 3108 | |||
| J05AH02 | Oseltamivir | Tamiflu | Capsule, hard | 75 | mg | 10 | Roche Registration Limited, Обединено Кралство | 150 | mg | 30.4 | 4.9 | 24.5 | 100% | J10.0,J10.1,J10.8,J11.1 | НСР-1923/27.11.2013; НСР-5748/26.02.2015 | 16.03.2015 | 08.09.2012 | Активен | 3633 | ||
| J05AH02 | Oseltamivir | ||||||||||||||||||||
| J05AH02 | Oseltamivir | TAMIFLU | Powder for oral suspension | 12 mg/ml - 30 g | mg | 1 | Roche Registration Limited, Обединено Кралство | 1 | mg | 31.3 | 0.00348 | 31.3 | 100% | J10,J12 | КЦРР-1326/21.08.2012 | 16.01.2014 | Заличен | 512 | |||
| J05AR01 | Lamivudine/ Zidovudine | ||||||||||||||||||||
| J05AR01 | Zidovudine and lamivudine | COMBIVIR | Film‐coated tablet | 150 mg/300 mg | mg | 60 | Viiv Healthcare UK Ltd.,, Обединено Кралство | 2 | tabl | 126.71 | 4.22367 | 126.71 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | № 120/ 09.12.2010; № 123/13.12.2010; НСР-3979/30.06.2014; КП-322/17.06.2015 и НСР-5806/12.03.2015 | 16.07.2015 | 08.09.2012 | 16.01.2014 | Активен | 3007 | |
| J05AR02 | Abacavir/ Lamivudin | ||||||||||||||||||||
| J05AR02 | Abacavir, lamivudine | KIVEXA | Film‐coated tablet | 600 mg/ 300 mg | 30 | Viiv Healthcare UK Ltd.,, Обединено Кралство | 1 | UD | 719.24 | 23.97467 | 719.24 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | ; НСР-9122/27.04.2016 | 02.06.2016 | 08.09.2012 | Активен | 1727 | |||
| J05AR03 | Emtricitabine/Tenofovir sidoproxil | ||||||||||||||||||||
| J05AR03 | Emtricitabine, Tenofovir disoproxil | Truvada | Film‐coated tablet | 200 mg/245 mg | UD | 30 | Gilead Sciences International Ltd., Обединено Кралство | 1UD (= 1 tab.) | UD | 990.84 | 30.28885 | 908.67 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | НСР-5064/21.11.2014; Протокол 133/27.08.2015.; НСР-7001/24.08.2015 | 16.09.2015 | Активен | 3360 | |||
| J05AR10 | Lopinavir/ Ritonavir | ||||||||||||||||||||
| J05AR10 | Lopinavir, Ritonavir | Kaletra | Film‐coated tablet | 100 mg/25 mg | mg | 60 | AbbVie Ltd, Обединено Кралство | 800 /refers to lopinavir/ | mg | 198.4 | 24.90433 | 186.78 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | № 177/ 21.06.2011; КЦРР-558/04.05.2012 г.; НСР-493/11.07.2013; НСР-811/16.09.2013НСР-3330/24.04.2014;НСР-5295/ 18.12.2014 | 02.06.2016 | 08.09.2012 | Активен | 3470 | ||
| J05AR10 | Lopinavir, Ritonavir | Kaletra | Film‐coated tablet | 200 mg/50 mg | mg | 120 | AbbVie Ltd, Обединено Кралство | 800 /refers to lopinavir/ | mg | 747.13 | 24.90433 | 747.13 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | ; НСР-9121/27.04.2016 | 02.06.2016 | 08.09.2012 | Активен | 3471 | ||
| J05AR10 | Lopinavir/ Ritonavir | ||||||||||||||||||||
| J05AR10 | Lopinavir, Ritonavir | Kaletra | Oral solution | KALETRA oral solution 80 mg/20 mg/ml - 60 ml | mg | 5 | AbbVie Ltd, Обединено Кралство | 800 /refers to lopinavir/ | mg | 643.18 | 21.43933 | 643.18 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | № 177/ 21.06.2011; НСР-495/11.07.2013; НСР-812/07.08.2013; НСР-3520/16.05.2014;НСР-5294/ 18.12.2014.; НСР-7521/19.11.2015 | 02.01.2016 | 08.09.2012 | Активен | 3469 | ||
| J05AR13 | Lopinavir/ Ritonavir | ||||||||||||||||||||
| J05AR13 | Dolutegravir, Abacavir, Lamivudine | Triumeq | Film‐coated tablet | 50 mg/600 mg/300 mg | mg | 30 | Viiv Healthcare UK Ltd.,, Обединено Кралство | 1UD (= 1 tab.) | UD | 1942.99 | 64.76633 | 1942.99 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | НСР-7032/28.08.2015 | 02.07.2016 | Активен | 4063 | |||
| J05AX05 | Inosine pranobex | ||||||||||||||||||||
| J05AX05 | Inosine pranobex | ISOPRINOSINE | Tablet | 500 | mg | 50 | Ewopharma International s.r.o., Словакия | 3000 | mg | 29.95 | 3.59544 | 29.95 | 100% | A63.0,A81.1,B00.0,B00.1,B00.2,B00.4,B00.5,B00.7,B00.8,B00.9,B01.0,B01.1,B01.2,B01.8,B01.9,B02.1,B02.2,B02.3,B02.7,B02.8,B02.9,B05.0,B05.1,B05.2,B05.3,B05.4,B05.8,B05.9,B06.8,B06.9,B15.0,B15.9,B16.0,B16.1,B16.2,B16.9,B17.0,B17.1,B17.2,B17.8,B25.0,B25.1,B25.2,B25.8,B25.9,B26.0,B26.1,B26.2,B26.3,B26.8,B26.9,B27.0,B27.1,B27.8,B27.9,J10.0,J10.1,J10.8,J11.0,J11.1,J11.8,K12.0 | Протокол № 34/19.09.2013; КП-376/11.09.2015 и НСР-6323/28.05.2015 | 02.10.2015 | 08.09.2012 | Активен | 589 | ||
| J05AX07 | Enfuvirtide | ||||||||||||||||||||
| J05AX07 | Enfuvirtide | FUZEON | Powder and solvent for solution for injection | 90 mg/ml | mg | 60 | Roche Registration Limited, Обединено Кралство | 180 | mg | 2964.07 | 98.80233 | 2964.07 | 100% | B20.0,B20.9,B21.0,B21.3,B21.7,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | НСР-1919/27.11.2013; НСР-3413/30.04.2014 | 02.06.2014 | 08.09.2012 | Заличен | 2315 | ||
| J05AX08 | Raltegravir | ||||||||||||||||||||
| J05AX08 | Raltegravir | ISENTRESS | Film‐coated tablet | 400 | mg | 60 | Merck Sharp & Dohme Ltd., Обединено Кралство | 800 | mg | 1250.34 | 41.678 | 1250.34 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | № 114/ 19.10.2010; № 238/ 04.11.2011; КЦРР-2288/20.02.2013 г.; КП-11/16.01.2015 и НСР-3422/30.04.2014.; НСР-7508/19.11.2015 | 02.02.2015 | 08.09.2012 | 16.01.2014 | Активен | 3503 | |
| J05AX09 | Maraviroc | ||||||||||||||||||||
| J05AX09 | Maraviroc | Celsentri | Film‐coated tablet | 150 | mg | 60 | Viiv Healthcare UK Ltd.,, Обединено Кралство | 1 | mg | 1370.35 | 0.07613 | 685.18 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | № 16/ 24.06.2009; № 115/ 19.10.2010; № 122/ 09.12.2010; КЦРР-2030/21.01.2013 г.; КЦPP-2851/20.03.2013; НСР-1090/02.09.2013; НСР-3354/29.04.2014;НСР-5310/ 18.12.2014; НСР-8328/26.02.2016 | 02.04.2016 | 08.09.2012 | 16.01.2014 | Активен | 3472 | |
| J05AX09 | Maraviroc | Celsentri | Film‐coated tablet | 300 | mg | 60 | Viiv Healthcare UK Ltd.,, Обединено Кралство | 1 | mg | 1370.35 | 0.07613 | 1370.35 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | № 16/ 24.06.2009; № 115/ 19.10.2010; № 122/ 09.12.2010; КЦРР-2030/21.01.2013 г.; КЦPP-2852/20.03.2013; НСР-1090/02.09.2013; НСР-3380/29.04.2014;НСР-5311/ 18.12.2014; НСР-8333/26.02.2016 | 02.04.2016 | 08.09.2012 | 16.01.2014 | Активен | 3473 | |
| J05AX12 | Dolutegravir | ||||||||||||||||||||
| J05AX12 | Dolutegravir | Tivicay | Film‐coated tablet | 50 | mg | 30 | Viiv Healthcare UK Ltd.,, Обединено Кралство | 1 | mg | 1250.34 | 0.83356 | 1250.34 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,B21.0,B21.2,B21.3,B21.7,B21.8,B21.9,B22.0,B22.1,B22.2,B22.7,B23.0,B23.1,B23.2,B23.8,B24,Z21 | НСР-4729/29.09.2014; НСР-6183/08.05.2015 | 02.06.2015 | Активен | 3922 | |||
| J06AA | Anthrax antitoxin | ||||||||||||||||||||
| J06AA | Anthrax antitoxin | ANTIANTHRAX SERUM BUL BIO | Solution for injection | amp. 10 ml (1 dose) | 10 | БУЛ БИО-НЦЗПБ ЕООД, България | 1 | ml | 228.38 | 2.2838 | 228.38 | 100% | A22.0,A22.1,A22.2,A22.7,A22.8,A22.9,Z29.1 | № 16/ 24.06.2009 | 08.09.2012 | 16.01.2014 | Активен | 552 | |||
| J06AA01 | Diphteria antitoxin | ||||||||||||||||||||
| J06AA01 | diphtheria antitoxin | Antidiphtheria serum Bul Bio | Solution for injection | 5000 | IU | x 1 | БУЛ БИО-НЦЗПБ ЕООД, България | 1 | IU | 156 | 0.00522 | 26.1 | 100% | A36.0,A36.1,A36.2,A36.3,A36.8,A36.9,Z23.6 | НСР-9380/01.06.2016 | 02.07.2016 | Активен | 15210 | |||
| J06AA01 | diphtheria antitoxin | Antidiphtheria serum Bul Bio | Solution for injection | 5000 IU | IU | 10 | БУЛ БИО-НЦЗПБ ЕООД, България | 1 | IU | 260.83 | 0.00522 | 260.83 | 100% | A36.0,A36.1,A36.2,A36.3,A36.8,A36.9,Z23.6 | № 16/ 24.06.2009 | 08.09.2012 | 16.01.2014 | Активен | 550 | ||
| J06AA02 | Tetanus antitoxin | ||||||||||||||||||||
| J06AA02 | Tetanus antitoxin | Antitetanus serum Bul Bio | Solution for injection | amp, 1500 IU - 1 dose | IU | 1 | БУЛ БИО-НЦЗПБ ЕООД, България | 1 | IU | 71.14 | 0.02304 | 34.56 | 100% | A35,Z29.1 | НСР-7504/19.11.2015.; НСР-8374/29.02.2016. (допуска предварително изпълнение) | 02.03.2016 | Активен | 4144 | |||
| J06AA02 | Tetanus antitoxin | Antitetanus serumm Bul Bio | Solution for injection | amp, 1500 IU - 1 dose | IU | 50 | БУЛ БИО-НЦЗПБ ЕООД, България | 1 | IU | 1728 | 0.02304 | 1728 | 100% | A35,Z29.1 | № 16/ 24.06.2009 | 08.09.2012 | 16.01.2014 | Активен | 549 | ||
| J06AA03 | Viper venom antiserum | ||||||||||||||||||||
| J06AA03 | Viper venom antiserum | SNAKE VENOM ANTISERUM BUL BIO | Solution for injection | 100 AE/amp. | mg | 10 | БУЛ БИО-НЦЗПБ ЕООД, България | 1000 | mg | 612 | 0.612 | 612 | 100% | T63.0 | № 16/ 24.06.2009 | 08.09.2012 | 16.01.2014 | Активен | 67 | ||
| J06AA03 | Viper venom antiserum | SNAKE VENOM ANTISERUM BUL BIO | Solution for injection | 100 AE/amp. | mg | 1 | БУЛ БИО-НЦЗПБ ЕООД, България | 1000 | mg | 68.64 | 0.612 | 61.2 | 100% | T63.0 | НСР-8256/22.02.2016 | 02.04.2016 | Активен | 4209 | |||
| J06AA04 | Clostridium botulijum type A, Clostridium botulinum type B, Clostridium botulinum type E | ||||||||||||||||||||
| J06AA04 | Clostridium botulinum type A, Clostridium botulinum type B, Clostridium botulinum type E, | ANTIBOTULINUM SERUM BUL BIO | Solution for injection | amp, 1500 IU - 1 dose | 1 | БУЛ БИО-НЦЗПБ ЕООД, България | 1 | IU | 37.39 | 0.02493 | 37.39 | 100% | A05.1,Z29.1 | № 16/ 24.06.2009 | 08.09.2012 | 16.01.2014 | Активен | 551 | |||
| J06BA00 | Immunoslobuline, Human Anti-Krimean Haemorrhagic fever | ||||||||||||||||||||
| J06BA00 | Immunoglobulin Human Anti-Krimean Haemorrhagie Fever | CHF-BULIN | Solution for injection | 120g/l - 3 ml | 10 | БУЛ БИО-НЦЗПБ ЕООД, България | 1 | mg | 810 | 0.225 | 810 | 100% | A98.0,Z29.1 | № 16/ 24.06.2009 | 08.09.2012 | 16.01.2014 | Активен | 548 | |||
| J06BA00 | Immunoglobuline, normal human for extravascular adm. Histamine dihydrochloride | ||||||||||||||||||||
| J06BA00 | Immunoglobuline, normal human for extravascular adm. | ALLERGOPREVENT | Solution for injection | 6 mg/ ml; 0,075 mcg/ ml - 2 ml(1 dose) | mg | 50 | БУЛ БИО-НЦЗПБ ЕООД, България | 1 | mg | 89.04 | - | 89.04 | 100% | G43,J30,L20,L20.8,L50,T78.3 | КЦРР-523/20.04.2012 | 08.09.2012 | 16.01.2014 | Заличен | 19 | ||
| J06BA01 | Immunoglobuline, normal human for extravascular adm. | ||||||||||||||||||||
| J06BA01 | Immunoglobuline, normal human for extravascular adm. | GAMMANORM | Solution for injection | 165 mg/ml - 20 ml | mg | 1 | Octapharma (IP) Ltd., Обединено Кралство | 1 | mg | 317.11 | 0.0208 | 68.64 | 100% | C90.0,C91.1,D80.0,D80.1,D80.2,D80.3,D80.4,D80.5,D80.6,D80.7,D80.8,D80.9,D81.0,D81.1,D81.2,D81.3,D81.4,D81.5,D81.6,D81.7,D81.9,D82.0,D82.1,D82.2,D82.3,D82.4,D82.8,D82.9,D83.0,D83.1,D83.2,D83.8,D83.9,D84.8 | № 204/ 24.10.2011; КЦРР-1778/06.12.2012 | 08.09.2012 | Активен | 2158 | |||
| J06BA01 | Immunoglobuline, normal human for extravascular adm. | GAMMANORM | Solution for injection | 165 mg/ml - 10 ml | mg | 1 | Octapharma (IP) Ltd., Обединено Кралство | 1 | mg | 148.9 | 0.0208 | 34.32 | 100% | C90.0,C91.1,D80.0,D80.1,D80.3,D80.4,D80.5,D80.6,D80.7,D80.8,D80.9,D81.0,D81.1,D81.2,D81.3,D81.4,D81.5,D81.6,D81.7,D81.9,D82.0,D82.1,D82.2,D82.3,D82.8,D82.9,D83.0,D83.1,D83.2,D83.8,D83.9,D84.8,Z29.1 | № 204/ 24.10.2011; КЦРР-1778/06.12.2012; НСР-146/07.06.20013 | 08.09.2012 | Активен | 1471 | |||
| J06BA01 | Immunoglobuline, normal human for extravascular adm. | HUMAN NORMAL IMMUNOGLOBULIN 10% - BB | Solution for injection | 100 mg/ml - 3 ml | mg | 10 | БУЛ БИО-НЦЗПБ ЕООД, България | 1 | mg | 62.4 | 0.0208 | 62.4 | 100% | Z29.1 | НСР-9816/21.07.2016. | 02.09.2016. | 08.09.2012 | 16.01.2014 | Активен | 18 | |
| J06BA02 | Immunoglobulins, normal human, for intravascular adm. | ||||||||||||||||||||
| J06BA02 | Immunoglobulins, normal human, for intravascular adm. | IMMUNOVENIN-INTACT 5% IgG | Solution for infusion | 50 mg/ml - 5 ml | mg | 10 | БУЛ БИО-НЦЗПБ ЕООД, България | mg | 128.54 | - | 128.54 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,C90.0,C91.1,D69.3,D80.0,D80.1,D80.2,D80.3,D80.4,D80.5,D80.6,D80.7,D80.8,D80.9,D81.0,D81.1,D81.2,D81.3,D81.4,D81.5,D81.6,D81.7,D81.9,D82.0,D82.1,D82.2,D82.3,D82.4,D82.8,D82.9,D83.0,D83.1,D83.2,D83.8,D83.9,D84.8,G61.0,M30.3,Z94.8 | КЦРР-1170/08.08.2012; НСР-9817/21.07.2016. | 02.09.2016. | 08.09.2012 | 16.01.2014 | Активен | 1318 | ||
| J06BA02 | Human normal immunoglobulin | ||||||||||||||||||||
| J06BA02 | Immunoglobuline, normal human for extravascular adm. | KIOVIG | Solution for infusion | 1 g/ 10 ml | mg | 1 | Baxter AG, Австрия | mg | 88.28 | 0.08828 | 88.28 | 100% | B20.1,C90.0,C91.1,D69.3,D80,D83,D84.8,G61.0,G61.8,G61.9,M30.3,Z94.9 | № 66/ 8.04.2010; КЦРР-430/19.04.2012 г.; КЦРР-770/07.06.2012 | 10.07.2012 | 08.09.2012 | Заличен | 1167 | |||
| J06BA02 | Immunoglobuline, normal human for extravascular adm. | KIOVIG | Solution for infusion | 10 g/100 ml(100 mg/ml) | mg | 1 | Baxter AG, Австрия | mg | 923.05 | 0.08828 | 882.8 | 100% | B20.1,C90.0,C91.1,D69.3,D80,D83,D84.8,G61.0,G61.8,G61.9,M30.3,Z94.9 | № 66/ 8.04.2010; КЦРР-430/19.04.2012 г.; КЦРР-770/07.06.2012 | 10.07.2012 | 08.09.2012 | Заличен | 1170 | |||
| J06BA02 | Immunoglobuline, normal human for extravascular adm. | KIOVIG | Solution for infusion | 2.5 g/25 ml (100 mg/ml) | mg | 1 | Baxter AG, Австрия | mg | 222.43 | 0.08828 | 220.7 | 100% | B20.1,C90.0,C91.1,D69.3,D80,D83,D84.8,G61.0,G61.8,G61.9,M30.3,Z94.9 | № 66/ 8.04.2010; КЦРР-430/19.04.2012 г.; КЦРР-770/07.06.2012 | 10.07.2012 | 08.09.2012 | Заличен | 1168 | |||
| J06BA02 | Immunoglobuline, normal human for extravascular adm. | KIOVIG | Solution for infusion | 20 g/ 200 ml (100 mg/ ml) | mg | 1 | Baxter AG, Австрия | mg | 1902.19 | 0.08828 | 1765.6 | 100% | B20.1,C90.0,C91.1,D69.3,D80,D83,D84.8,G61.0,G61.8,G61.9,M30.3,Z94.9 | № 66/ 8.04.2010; КЦРР-430/19.04.2012 г.; КЦРР-770/07.06.2012 | 10.07.2012 | 08.09.2012 | Заличен | 1171 | |||
| J06BA02 | Immunoglobuline, normal human for extravascular adm. | KIOVIG | Solution for infusion | 5 g/ 50 ml (100 mg/ ml) | mg | 1 | Baxter AG, Австрия | mg | 469.96 | 0.08828 | 441.4 | 100% | B20.1,C90.0,C91.1,D69.3,D80,D83,D84.8,G61.0,G61.8,G61.9,M30.3,Z94.9 | № 66/ 8.04.2010; КЦРР-430/19.04.2012 г.; КЦРР-770/07.06.2012 | 10.07.2012 | 08.09.2012 | Заличен | 1169 | |||
| J06BA02 | Immunoglobulins, normal human, for intravascular adm. | OCTAGAM 10% | Solution for infusion | 100 mg/ml - 100 ml | mg | 1 | Octapharma (IP) Ltd., Обединено Кралство | mg | 940.16 | 0.09607 | 960.7 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,C90.0,C91.1,D69.3,D80.0,D80.1,D80.2,D80.3,D80.4,D80.5,D80.6,D80.7,D80.8,D80.9,D81.0,D81.1,D81.2,D81.3,D81.4,D81.5,D81.6,D81.7,D81.9,D82.0,D82.1,D82.2,D82.3,D82.4,D82.8,D82.9,D83.0,D83.1,D83.2,D83.8,D83.9,D84.8,G61.0,M30.3,Z94.8 | № 208/ 04.11.2011 | 02.09.2013 | 08.09.2012 | Активен | 1590 | |||
| J06BA02 | Immunoglobulins, normal human, for intravascular adm. | OCTAGAM 10% | Solution for infusion | 100 mg/ml - 20 ml | mg | 1 | Octapharma (IP) Ltd., Обединено Кралство | mg | 199.67 | 0.09607 | 192.14 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,C90.0,C91.1,D69.3,D80.0,D80.1,D80.2,D80.3,D80.4,D80.5,D80.6,D80.7,D80.8,D80.9,D81.0,D81.1,D81.2,D81.3,D81.4,D81.5,D81.6,D81.7,D81.9,D82.0,D82.1,D82.2,D82.3,D82.4,D82.8,D82.9,D83.0,D83.1,D83.2,D83.8,D83.9,D84.8,G61.0,M30.3,Z94.8 | № 208/ 04.11.2011 | 02.09.2013 | 08.09.2012 | Активен | 1588 | |||
| J06BA02 | Immunoglobulins, normal human, for intravascular adm. | OCTAGAM 10% | Solution for infusion | 100 mg/ml - 50 ml | mg | 1 | Octapharma (IP) Ltd., Обединено Кралство | mg | 481.33 | 0.09607 | 480.35 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,C90.0,C91.1,D69.3,D80.0,D80.1,D80.2,D80.3,D80.4,D80.5,D80.6,D80.7,D80.8,D80.9,D81.0,D81.1,D81.2,D81.3,D81.4,D81.5,D81.6,D81.7,D81.9,D82.0,D82.1,D82.2,D82.3,D82.4,D82.8,D82.9,D83.0,D83.1,D83.2,D83.8,D83.9,D84.8,G61.0,M30.3,Z94.8 | № 208/ 04.11.2011 | 02.09.2013 | 08.09.2012 | Активен | 1589 | |||
| J06BA02 | Immunoglobulins, normal human | Privigen | Solution for infusion | 100 mg/ml - 100 ml | mg | 1 | CSL Behring GmbH, Германия | mg | 923.93 | 0.09607 | 960.7 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,C90.0,C91.1,D69.3,D80.0,D80.1,D80.2,D80.3,D80.4,D80.5,D80.6,D80.7,D80.8,D80.9,D81.0,D81.1,D81.2,D81.3,D81.4,D81.5,D81.6,D81.7,D81.9,D82.0,D82.1,D82.2,D82.3,D82.4,D82.8,D82.9,D83.0,D83.1,D83.2,D83.8,D83.9,D84.8,G61.0,M30.3,Z94.8 | № 190/ 22.08.2011; НСР-155/18.06.2013 | 02.09.2013 | 08.09.2012 | Активен | 2008 | |||
| J06BA02 | Immunoglobulins, normal human | Privigen | Solution for infusion | 100 mg/ml - 50 ml | mg | 1 | CSL Behring GmbH, Германия | mg | 467.56 | 0.09607 | 480.35 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,C90.0,C91.1,D69.3,D80.0,D80.1,D80.2,D80.3,D80.4,D80.5,D80.6,D80.7,D80.8,D80.9,D81.0,D81.1,D81.2,D81.3,D81.4,D81.5,D81.6,D81.7,D81.9,D82.0,D82.1,D82.2,D82.3,D82.4,D82.8,D82.9,D83.0,D83.1,D83.2,D83.8,D83.9,D84.8,G61.0,M30.3,Z94.8 | № 190/ 22.08.2011; НСР-212/20.06.2013 | 02.09.2013 | 08.09.2012 | Активен | 2007 | |||
| J06BA02 | Immunoglobulins, normal human | Privigen | Solution for infusion | 100 mg/ml - 25 ml | mg | 1 | CSL Behring GmbH, Германия | mg | 242.68 | 0.09607 | 240.18 | 100% | B20.0,B20.1,B20.2,B20.3,B20.4,B20.5,B20.6,B20.7,B20.8,B20.9,C90.0,C91.1,D69.3,D80.0,D80.1,D80.2,D80.3,D80.4,D80.5,D80.6,D80.7,D80.8,D80.9,D81.0,D81.1,D81.2,D81.3,D81.4,D81.5,D81.6,D81.7,D81.9,D82.0,D82.1,D82.2,D82.3,D82.4,D82.8,D82.9,D83.0,D83.1,D83.2,D83.8,D83.9,D84.8,G61.0,M30.3,Z94.8 | № 190/ 22.08.2011; НСР-154/18.06.2013 | 02.09.2013 | 08.09.2012 | Активен | 2006 | |||
| J07AG01 | Haemophilus type b conjugated vaccine | ||||||||||||||||||||
| J07AG01 | Hemophilus Influenzae B, Purified Antigen Conjugated | ACT-HIB | Powder and solvent for suspension for injection | полизахарид на Haemophilus influenzae тип b..10 микрограма | ml | 1 | Sanofi Pasteur S.A., Франция | ml | 15.8 | - | 15.8 | 100% | Z23.8 | № 16/ 24.06.2009 г.; КЦРР-722/07.06.2012 г.; КЦРР-2340/21.02.2013 | 08.09.2012 | 16.01.2014 | Заличен | 1387 | |||
| J07AG01 | Haemophilus tipe b conjugate vaccine | ||||||||||||||||||||
| J07AG01 | Hemophilus Influenzae B, Purified Antigen Conjugated | Hiberix | Powder and solvent for solution for injection | Haemophilus influenzae type B polysaccharide – 10 μg, conjugated to 30 μg tetanus toxoid | mg | 1 | ГлаксоСмитКлайн ЕООД, България | - | 23.36 | - | 23.36 | 100% | Z23.8 | КЦРР-888/28.06.2012 г.; КЦРР-2939/20.03.2013 | 26.04.2013 | 08.09.2012 | Заличен | 1281 | |||
| J07AJ51 | Diphtheria, tetanus and pertussis vaccine (adsorbed) | ||||||||||||||||||||
| J07AJ51 | pertussis, inactivated, whole cell, combinations with toxoids | DIFTETKOK WITHOUT PRESERVATIVE | Suspension for injection | amp. 0,5 ml (1 dose) | ml | 10 | БУЛ БИО-НЦЗПБ ЕООД, България | ml | 19.08 | - | 19.08 | 100% | Z27.1 | № 16/ 24.06.2009 | 08.09.2012 | 16.01.2014 | Активен | 65 | |||
| J07AJ52 | Diphtheria, Tetanus and Pertussis (acellular, component) vaccine | ||||||||||||||||||||
| J07AJ52 | pertussis, purified antigen, combinations with toxoids | Boostrix | Suspension for injection | 1 dose(0,5 ml) | 1 pre-filled syringe 0.5 ml + 2 needles | ГлаксоСмитКлайн ЕООД, България | ml | 27.77 | - | 27.77 | 100% | Z27.1 | 08.09.2012 | 16.01.2014 | Активен | 127 | |||||
| J07AJ52 | Diphtheria, Tetanus, Pertussis (acellular component) Vaccine (adsorbed, reduced antigen(s) content) | ||||||||||||||||||||
| J07AJ52 | pertussis, purified antigen, combinations with toxoids | Infanrix | Suspension for injection | Diphtheria toxoid ≥ 30 IU / Filamentous haemagglutinin 25 μg / Pertussis toxoid 25 μg / Tetanus toxoid ≥ 40 IU / Pertactin 8 μg | mg | 1 | GlaxoSmithKline Biologicals S.A., Белгия | - | 22.91 | - | 22.91 | 100% | Z27.1 | КЦРР-2476/27.02.2013 | 08.09.2012 | Заличен | 130 | ||||
| J07AJ52 | Diphtheria, Tetanus, Pertussis (acellular component) Vaccine (adsorbed, reduced antigen(s) content) | ||||||||||||||||||||
| J07AJ52 | pertussis, purified antigen, combinations with toxoids | ADACEL susp. inj 0,5ml 1 vial x 1 | Suspension for injection | 0.5 | ml | 1 | Sanofi Pasteur S.A., Франция | - | 30.6 | - | 30.6 | 100% | Z27.1 | № 151/ 14.03.2011; КЦРР-2314/20.02.2013 | 08.09.2012 | Активен | 1753 | ||||
| J07AL01 | Pneumococcal polysaccharide vaccine | ||||||||||||||||||||
| J07AL01 | Pneumococcus, purified polysaccharides antigen | Pneumo 23 | Powder and solvent for suspension for injection | 0.5 | ml | 1 | Sanofi Pasteur S.A., Франция | ml | 20.87 | - | 20.87 | 100% | Z23.8 | № 62/ 15.03.2010; HCР-290/28.06.2013.; НСР-6030/09.04.2015 | 02.05.2015 | 08.09.2012 | 16.01.2014 | Заличен | 1955 | ||
| J07AL02 | Pneumococcal saccharide conjugated vaccine, absorbed | ||||||||||||||||||||
| J07AL02 | Pneumococcus, purified polysaccharides antigen | Prevenar | Suspension for injection | pneumococcal polysaccharide serotype 4 - 2 mcg; pneumococcal polysaccharide serotype 6B - 4 mcg; pneumococcal polysaccharide serotype 9V - 2 mcg; pneumococcal polysaccharide serotype 14 - 2 mcg; pneumococcal oligosaccharide serotype 18c - 2 mcg; pneumococ | mg | 1 | Pfizer Limited, Обединено Кралство | - | 96.61 | - | 96.61 | 100% | Z23.8 | КЦPP-1460/02.10.2012 г.; ; КЦPP-970/16.07.2012 г.; НСР-619/23.07.2013; НСР-3412/30.04.2014 | 02.06.2014 | 08.09.2012 | Заличен | 2009 | |||
| J07AL02 | Pneumococcal saccharide conjugated vaccine, absorbed | ||||||||||||||||||||
| J07AL02 | Pneumococcus, purified polysaccharides antigen conjugated | Prevenar 13 | Suspension for injection | 0.5 | ml | 1 pre-fylled syringe | Pfizer Limited, Обединено Кралство | 0.5 | mg | 106.13 | 101.771 | 106.13 | 100% | Z23.8 | № 145/ 28.01.2011; КЦРР-970/16.07.2012 г.; КЦРР-1914/15.12.2012 г.; НСР-2500/24.01.2014; НСР-628/23.07.2013 и КП-46/21.05.2014.; НСР-7253/21.10.2015 | 16.11.2015 | Заличен | 2862 | |||
| J07AL02 | Pneumococcus, purified polysaccharides antigen conjugated | Prevenar 13 | Suspension for injection | 0.5 | ml | 10 | Pfizer Limited, Обединено Кралство | 0.5 | mg | 1017.71 | 101.771 | 1017.71 | 100% | Z23.8 | № 145/ 28.01.2011; КЦРР-1914/15.12.2012 г.; КЦРР-2217/06.02.2013 | 14.03.2013 | 08.09.2012 | 16.01.2014 | Активен | 1653 | |
| J07AL52 | Pneumococcal polysaccharide conjugate vaccine | ||||||||||||||||||||
| J07AL52 | Pneumococcus, purified polysaccharides antigen conjugated | SYNFLORIX | Suspension for injection | 0.5 ml | 1 pre-filled syringe + 1 needle | GlaxoSmithKline Biologicals S.A., Белгия | - | 76.84 | - | 76.84 | 100% | Z23.8 | № 25/ 03.08.2009; № 89/ 17.06.2010; НСР-1281/25.09.2013; НСР-3842/16.06.2014 | 16.07.2014 | 08.09.2012 | Активен | 2958 | ||||
| J07AM01 | Tetanus Toxoid | ||||||||||||||||||||
| J07AM01 | Tetanus toxoid | TETATOX | Suspension for injection | 0,5 ml (1 dose) | 10 | БУЛ БИО-НЦЗПБ ЕООД, България | ml | 11.17 | - | 11.17 | 100% | Z23.5 | № 16/ 24.06.2009 г.; КЦРР-1252/15.08.2012 | 8.9.2012. | 16.01.2014 | Активен | 1344 | ||||
| J07AM51 | Diphtheria and tetanus vaccine (adsorbed, reduced antigen (s) content) | ||||||||||||||||||||
| J07AM51 | tetanus toxoid, combinations with diphtheria toxoid | TETADIF | Suspension for injection | 0,5 ml (1 dose) | 10 | БУЛ БИО-НЦЗПБ ЕООД, България | ml | 13.99 | - | 13.99 | 100% | Z27.8 | № 16/ 24.06.2009 | 08.09.2012 | 16.01.2014 | Активен | 64 | ||||
| J07AM51 | Diphtheria and tetanus vaccine (ADSORBED) | ||||||||||||||||||||
| J07AM51 | tetanus toxoid, combinations with diphtheria toxoid | DIFTET | Suspension for injection | amp. 0,5 ml (1 dose) | 10 | БУЛ БИО-НЦЗПБ ЕООД, България | ml | 13.99 | - | 13.99 | 100% | Z27.8 | № 16/ 24.06.2009 | 8.9.2012. | 16.01.2014 | Активен | 63 | ||||
| J07AN01 | Mycobacterium bovis BCG | ||||||||||||||||||||
| J07AN01 | Mycobacterium bovis BCG | BCG VACCINE, FREEZE-DRIED | Powder and solvent for suspension for injection | 10 doses amp. + solv. 1 ml amp (200 doses) | 20 | БУЛ БИО-НЦЗПБ ЕООД, България | ml | 33.07 | - | 33.07 | 100% | Z23.2 | № 16/ 24.06.2009 | 08.09.2012 | 16.01.2014 | Активен | 17 | ||||
| J07AP03 | Typhoid polysaccharide vaccine | ||||||||||||||||||||
| J07AP03 | Typhoid Polysaccaride Vaccine | TYPHERIX | Solution for injection | 0,5 ml/1 dose | 1 pre-filled syrigne + 2 needels | ГлаксоСмитКлайн ЕООД, България | ml | 17.41 | - | 17.41 | 100% | Z23.1 | № 58/ 05.03.2010 | 08.09.2012 | 16.01.2014 | Активен | 844 | ||||
| J07AP03 | Typhoid Polysaccaride Vaccine | Typhim Vi | Solution for injection | 0,5 ml/1 dose | 1pre-filled syringe | Sanofi Pasteur S.A., Франция | ml | 21.05 | - | 21.05 | 100% | Z23.1 | № 16/ 24.06.2009 | 08.09.2012 | 16.01.2014 | Активен | 668 | ||||
| J07BB01 | Influenza vaccine (split virion, inactivated) | ||||||||||||||||||||
| J07BB01 | influenza, inactivated, split virus or surface antigen | FLUARIX | Suspension for injection | 15 mcg haemagglutinin | mg | 1 pre-filled syringe 0.5 ml | ГлаксоСмитКлайн ЕООД, България | ml | 8.8 | - | 8.8 | 100% | Z25.1 | № 126/ 13.12.2010; КЦРР-2462/27.02.2013 | 08.09.2012 | Активен | 1690 | ||||
| J07BB02 | Influenza vaccine (split virion, inactivated) | ||||||||||||||||||||
| J07BB02 | influenza, inactivated, split virus or surface antigen | VAXIGRIP | Suspension for injection | за доза от 0,5 ml - произведен в кокоши ембриони от групи здрави кокошки, хемаглутинин | ml | 20 | Sanofi Pasteur S.A., Франция | ml | 217.09 | - | 217.09 | 100% | Z25.1 | КЦРР-707/07.06.2012 г.; НСР-3379/29.04.2014 | 02.06.2014 | 08.09.2012 | 16.01.2014 | Заличен | 1388 | ||
| J07BB02 | influenza, inactivated, split virus or surface antigen | VAXIGRIP | Suspension for injection | 1 pre-filled syringe 0,5 ml with attached needle | Sanofi Pasteur S.A., Франция | ml | 10.12 | - | 10.12 | 100% | Z25.1 | № 58/ 05.03.2010; HCР-291/28.06.2013; НСР-9783/14.07.2016 | 42584 | Заличен | 1926 | ||||||
| J07BB02 | influenza, inactivated, split virus or surface antigen | Vaxigrip pediatric use | Suspension for injection | за доза от 0,25 ml - произведен в кокоши ембриони от групи здрави кокошки, хемаглутинин | ml | 1 | Sanofi Pasteur S.A., Франция | ml | 9.54 | - | 9.54 | 100% | Z25.1 | ; НСР-9256/05.05.2016 | 02.06.2016 | 08.09.2012 | 16.01.2014 | Заличен | 669 | ||
| J07BB02 | Influenza vaccine (split virion, inactivated) | ||||||||||||||||||||
| J07BB02 | influenza, inactivated, split virus or surface antigen | Influvac | Suspension for injection | 1 dose - 0,5 ml | 1 pre-filled syringe | BGP Products BV, Нидерландия | - | 8.8 | - | 8.8 | 100% | Z25.1 | КЦРР-431/19.04.2012 г.; КЦРР-1433/25.09.2012; НСР-963/12.08.2013 | 16.09.2013 | 08.09.2012 | 16.01.2014 | Активен | 2064 | |||
| J07BB02 | Influenza, inactivated, whole virus | PANDEMRIX | Solution for injection | 3,75 mcg/0,5 | ml | vials of suspension + 2 x 25 vials of emulsion - 500 doses | GlaxoSmithKline Biologicals S.A., Белгия | ml | 8226.49 | - | 8226.49 | 100% | Z25.1 | № 58/05.03.2010; НСР-9434/01.06.2016 | 02.07.2016 | 08.09.2012 | 16.01.2014 | Заличен | 843 | ||
| J07BC01 | Hepatit B antigen, purified | ||||||||||||||||||||
| J07BC01 | Hepatitis B, purified antigen | Engerix B | Suspension for injection | 20 mcg/1.0 ml | 1 pre-filled syringe | GlaxoSmithKline Biologicals S.A., Белгия | - | 21.89 | - | 21.89 | 100% | Z24.6 | № 209/ 04.11.2011; КЦРР-2557/14.03.2013 | 08.09.2012 | Активен | 1730 | |||||
| J07BC01 | Hepatitis B, purified antigen | Engerix B | Suspension for injection | 10 mcg/0.5 ml | 1 pre-filled syringe | GlaxoSmithKline Biologicals S.A., Белгия | - | 15.3 | - | 15.3 | 100% | Z24.6 | Задължителна; № 209/ 04.11.2011; НСР-3980/30.06.2014; НСР-8323/26.02.2016 | 02.04.2016 | 08.09.2012 | Активен | 2998 | ||||
| J07BC01 | Hepatitis B, purified antigen | HBVAXPRO | Suspension for injection | 5mcg/0.5 ml | 1 pre-filled syringe with 2 separate needles | Sanofi Pasteur MSD, SNC, Франция | - | 15.25 | - | 15.25 | 100% | Z24.6 | НСР-2904/05.03.2014 | Активен | 2564 | ||||||
| J07BC01 | Hepatit B antigen, purified | ||||||||||||||||||||
| J07BC01 | Hepatitis B, purified antigen | Engerix B | Suspension for injection | 10 mcg/0,5 ml | mg | 1 | GlaxoSmithKline Biologicals S.A., Белгия | - | 13.19 | - | 13.19 | 100% | Z24.6 | НСР-2807/17.02.2014 | Активен | 2516 | |||||
| J07BC01 | Hepatitis B, purified antigen | ENGERIX B | Suspension for injection | Hepatitis B surface antigen (HBsAg) 0,5 ml/10 mcg/ dose | mg | 1 | GlaxoSmithKline Biologicals S.A., Белгия | 1 dose | mg | 13.19 | - | 13.19 | 100% | Z24.6 | № 92/ 23.06.2010; ; КЦРР-1637/15.11.2012 | 08.09.2012 | 16.01.2014 | Заличен | 915 | ||
| J07BC01 | Hepatitis B, purified antigen | ENGERIX B | Suspension for injection | 20 mcg/1.0 ml - 1 dose | mcg | 1 | GlaxoSmithKline Biologicals S.A., Белгия | 1 dose | mg | 26.08 | - | 26.08 | 100% | Z24.6 | № 86/ 17.06.2010; № 209/ 04.11.2011; ; КЦРР-1638/15.11.2012 | 08.09.2012 | Заличен | 907 | |||
| J07BC02 | Hepatitis A vaccine (inactivated, adsorbed) | ||||||||||||||||||||
| J07BC02 | Hepatitis A, inactivated, whole virus | AVAXIM 160 U adult | susp. Inj. Pre-filled syringe 0, 5 ml | Хепатит А вирус, щам GBM, инактивиран и адсорбиран ….. 160 единици | ml | 1 | Sanofi Pasteur S.A., Франция | ml | 43.42 | - | 43.42 | 100% | Z24.6 | ; НСР-9461/01.06.2016 | 02.07.2016 | Заличен | 1718 | ||||
| J07BC02 | Hepatitis A, inactivated, whole virus | AVAXIM 80 U pediatric | susp. Inj. Pre-filled syringe 0, 5 ml | Inactivated Hepatitis A virus / (strain GMB) / 80 U | ml | 1 | Sanofi Pasteur S.A., Франция | ml | 29 | - | 29 | 100% | Z24.6 | ; НСР-9460/01.06.2016 | 02.07.2016 | Заличен | 1717 | ||||
| J07BC02 | Hepatitis A vaccine (inactivated, adsorbed) | ||||||||||||||||||||
| J07BC02 | Hepatitis A, inactivated, whole virus | Havrix 720 | Suspension for injection | 0.5ml (Junior monodose) | 1 pre-filled syringe | GlaxoSmithKline Biologicals S.A., Белгия | - | 24.65 | - | 24.65 | 100% | Z24.6 | HCР-301/03.07.2013; КП-303/17.06.2015 и НСР-5955/01.04.2015 | 16.07.2015 | 08.09.2012 | Активен | 1925 | ||||
| J07BC20 | Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed) | ||||||||||||||||||||
| J07BC20 | Hepatitis A (inactivated), hepatitis B (rDNA) (HAB) vaccine (adsorbed) | TWINRIX ADULT | Suspension for injection | 1ml | 1 pre-filled syringe + 1 separate needle | GlaxoSmithKline Biologicals S.A., Белгия | - | 48.65 | 48.65 | 48.65 | 100% | Z24.6,Z27.8 | КЦРР-743/07.06.2012 г.; НСР-7782/28.12.2015 | 02.02.2016 | 08.09.2012 | Активен | 129 | ||||
| J07BC20 | Hepatitis A (inactivated), hepatitis B (rDNA) (HAB) vaccine (adsorbed) | TWINRIX ADULT | Suspension for injection | 20 mcg/1 ml | 1 dose=1 ml | 1 | GlaxoSmithKline Biologicals S.A., Белгия | 1 dose = 1 ml | - | 50.33 | 50.33 | 50.33 | 100% | Z24.6,Z27.8 | № 86/ 17.06.2010; ; КЦРР-1641/15.11.2012 | 13.12.2012 | 08.09.2012 | Заличен | 1244 | ||
| J07BD52 | Measles, mumps and rubella vaccine, live | ||||||||||||||||||||
| J07BD52 | Measles, mumps and rubella vaccine (live) | M-M-RVAXPRO | Powder and solvent for suspension for injection | 0,5 ml | 1 vial + 1 pre-filled syringe + 2 needles | Sanofi Pasteur MSD, SNC, Франция | 1 | dose | 19.03 | 18.66 | 18.66 | 100% | Z27.4 | НСР-2854/21.02.2014 | 16.11.2015 | Активен | 2517 | ||||
| J07BD52 | Measles, mumps and rubella vaccine (live) | Priorix | Powder and solvent for suspension for injection | 1 dose 0.5 ml | 1 vial with powder + 1 pre-filled syr. 0,5 ml solv + 2 separate needles | GlaxoSmithKline Biologicals S.A., Белгия | 1 | dose | 19.03 | 18.66 | 18.66 | 100% | Задължителна | Z27.4 | КЦРР-718/07.06.2012 | 16.11.2015 | 08.09.2012 | Активен | 1234 | ||
| J07BD52 | Measles, mumps and rubella vaccine (live) | Priorix | Powder and solvent for suspension for injection | 1 dose 0.5 ml | 1 vial with powder + 1 ampoule with solvent | GlaxoSmithKline Biologicals S.A., Белгия | 1 | dose | 18.66 | 18.66 | 18.66 | 100% | Z27.4 | НСР-7216/15.10.2015 | Активен | 4084 | |||||
| J07BD52 | Measles, mumps and rubella vaccine (live) | Priorix | Powder and solvent for suspension for injection | 1 dose 0.5 ml | 100 vial with powder + 100 ampoule with solvent | GlaxoSmithKline Biologicals S.A., Белгия | 1 | dose | 1872 | 18.66 | 1866 | 100% | съгл. РУ | Z27.4 | НСР-8093/17.02.2016. | 02.03.2016 | Активен | 4184 | |||
| J07BD52 | Measles, mumps and rubella vaccine (live) | Priorix | Powder and solvent for suspension for injection | Live attenuated measles virus (Schwarz strain) 1; Live attenuated mumps virus (RIT 4385 strain) 1; Live attenuated rubella virus (Wistar RA 27/3 strain) 1 | 1 | GlaxoSmithKline Biologicals S.A., Белгия | - | 18.66 | - | 18.66 | 100% | Z27.4 | № 62/ 15.03.2010; № 65/ 08.04.2010; КЦРР-1642/15.11.2012 | 08.09.2012 | 16.01.2014 | Заличен | 855 | ||||
| J07BF02 | Poliomyelitis vaccine, (live attenuated) | ||||||||||||||||||||
| J07BF02 | Poliomyelitis vaccine, (live attenuated) | POLIO SABIN (ORAL) | Oral drops, suspension | 10 doses (1 ml) | 100 vial + dropper applicator | ГлаксоСмитКлайн ЕООД, България | - | 798.24 | - | 798.24 | 100% | Z24.0 | № 25/ 03.08.2009 | 08.09.2012 | Активен | 687 | |||||
| J07BF03 | Poliomyelitis vaccine (inactivated) | ||||||||||||||||||||
| J07BF03 | Poliomyelitis vaccine, inactivated | Imovax Polio | Suspension for injection | полиовирус тип 1, щам mahoney (инактивиран) …. 40 DU; полиовирус тип 2, щам MEF - 1 (инактивиран)…… 8 DU; полиовирус тип 3, щам saukett (инактивиран) …. 32 DU | ml | 1 | Sanofi Pasteur S.A., Франция | ml | 7.67 | - | 7.67 | 100% | Z24.0 | № 16/24.06.2009 г.; КЦРР-1065/26.07.2012 г.; НСР-2155/14.12.2013 | 16.02.2014 | 08.09.2012 | 16.01.2014 | Заличен | 1390 | ||
| J07BF03 | Poliomyelitis vaccine, inactivated | ||||||||||||||||||||
| J07BF03 | Poliomyelitis vaccine, inactivated | Poliorix | Solution for injection | 0.5ml (1dose) | 1 vial | GlaxoSmithKline Biologicals S.A., Белгия | - | 17.46 | - | 17.46 | 100% | Z24.0 | Задължителна | 08.09.2012 | Активен | 128 | |||||
| J07BG01 | Rabies vaccine for human use prepared in cell cultures (inactivated) | ||||||||||||||||||||
| J07BG01 | Rabies vaccine for human use prepared in cell cultures (inactivated) | VERORAB | Powder and solvent for suspension for injection | 2,5 IU/0,5 ml | vial (1 dose) + ampoule solvent 0,5 ml x 5 | Sanofi Pasteur S.A., Франция | 0.5 | ml | 141.08 | 20.93 | 104.65 | 100% | Z24.2 | НСР-6571/24.06.2015 | Активен | 4179 | |||||
| J07BG01 | Rabies vaccine for human use prepared in cell cultures (inactivated) | VERORAB | Powder and solvent for solution for injection | лиофилизат…. 1 ваксинална доза така че активността е равна на 2,5 IU преди и след нагряване при 37 ° С в продължение на един месец на Rabies virus, култивиран на Vero клетъчни култури | ml | 5 | Sanofi Pasteur S.A., Франция | ml | 93.05 | - | 93.05 | 100% | Z24.2 | № 16/24.06.2009 г.; НСР-6190/08.05.2015 | 08.09.2012 | 16.01.2014 | Заличен | 670 | |||
| J07BG01 | Rabies vaccine for human use prepared in cell cultures (inactivated) | VERORAB | Powder and solvent for suspension for injection | 2,5 IU/0,5 ml | 1 vial (1 dose) + 1 pre-filled syringe solvent 0.5 ml | Sanofi Pasteur S.A., Франция | 0.5 | ml | 20.93 | 20.93 | 20.93 | 100% | Z24.2 | № 16/24.06.2009 г.; НСР-1310/03.10.2013; НСР-1712/11.11.2013 | 02.12.2013 | 08.09.2012 | 16.01.2014 | Активен | 2156 | ||
| J07BH01 | Rotavirus vaccine, live | ||||||||||||||||||||
| J07BH01 | Rota virus, live attenuated | Rotarix | Powder and solvent for oral suspension | Human rotavirus RIX4414 strain (live, attenuated) ≥ 106.0 CCID50 | mg | 1 | GlaxoSmithKline Biologicals S.A., Белгия | - | 122.04 | - | 122.04 | 100% | Z25.8 | КЦРР-1671/20.11.2012 | 08.09.2012 | Заличен | 135 | ||||
| J07BH01 | Rotavirus vaccine, live | ||||||||||||||||||||
| J07BH01 | Rota virus, live attenuated | ROTARIX | Oral suspension | 1,5 ml prefilled oral applicator (glass) | 1 dose | GlaxoSmithKline Biologicals S.A., Белгия | 1400 | mg | 103.73 | - | 103.73 | 100% | Z25.8 | № 180/ 27.07.2011; НСР-4593/15.09.2014; НСР-6181/08.05.2015 | 02.06.2015 | 08.09.2012 | Активен | 3932 | |||
| J07BH02 | Rotavirus vaccine, live | ||||||||||||||||||||
| J07BH02 | Rota virus, live attenuated | RotaTeq | Oral solution | 2 ml | 1 | Sanofi Pasteur MSD, SNC, Франция | - | 63.52 | - | 63.52 | 100% | Z25.8 | НСР-2903/05.03.2014 | Активен | 2565 | ||||||
| J07BM01 | (Human papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)) Адсорбирана ваксина срещу човешки папиломавирус [Тип 6, 11, 16, 18] (рекомбинанта) | ||||||||||||||||||||
| J07BM01 | Papillomavirus (human types 6, 11, 16, 18) | SILGARD | Suspension for injection | 0,5 ml | 1 pre-filled syringe + 2 needles | Merck Sharp & Dohme Ltd., Обединено Кралство | ml | 211.62 | - | 211.62 | 100% | Z25.8 | № 16/24.06.2009 г.; КЦРР-742/07.06.2012 г.; КЦРР-1735/04.12.2012 | 04.01.2013 | 08.09.2012 | Активен | 1501 | ||||
| J07BM02 | Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) | ||||||||||||||||||||
| J07BM02 | Papillomavirus (Human Types 16, 18) | Cervarix | Suspension for injection | 1 dose (0,5 ml) | 1 pre-filled syringe + 2 needles | GlaxoSmithKline Biologicals S.A., Белгия | - | 110.94 | - | 110.94 | 100% | Z25.8 | КЦРР-1734/04.12.2012 г; НСР-3176/07.04.2014 | 02.05.2014 | 08.09.2012 | Активен | 2683 | ||||
| J07BX00 | Crimean Haemorrhagic fever vaccine; inactivated | ||||||||||||||||||||
| J07BX00 | Crimean Haemorrhagic fever vaccine; inactivated | ANTI-CHF VACCINE | Suspension for injection | amp. 1 ml (1 dose) | 50 | БУЛ БИО-НЦЗПБ ЕООД, България | ml | 1182 | 23.64 | 1182 | 100% | Z25.8 | КЦРР-1253/15.08.2012 | 08.09.2012 | 16.01.2014 | Активен | 1345 | ||||
| J07BX00 | Crimean Haemorrhagic fever vaccine; inactivated | Anti-CHF VACCINE, suspension for injection x 1 | Suspension for injection | amp. 1 ml (1 dose) | 1 | БУЛ БИО-НЦЗПБ ЕООД, България | 1 | ml | 44.93 | 23.64 | 23.64 | 100% | Z25.8 | НСР-7502/19.11.2015 | Активен | 4133 | |||||
| J07CA | Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus type b (Hib) conjugate vaccine (adsorbed). | ||||||||||||||||||||
| J07CA | diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B | Infanrix Hexa | Powder and suspension for suspension for injection | suspension: 0.5 ml | 1 vial + 1 prefilled syringe + 2 needles | GlaxoSmithKline Biologicals S.A., Белгия | 1 | dose | 71.27 | 71.27 | 71.27 | 100% | Z27.8 | КЦРР-2406/21.02.2013 г.; НСР-7707/17.12.2015 | 02.02.2016 | 08.09.2012 | Активен | 1754 | |||
| J07CA09 | diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B | Infanrix Hexa | Powder and suspension for suspension for injection | suspension: 0.5 ml | 10 vials + 10 prefilled syringes | GlaxoSmithKline Biologicals S.A., Белгия | 1 | dose | 857.98 | 71.27 | 712.7 | 100% | Z27.8 | НСР-4827/14.10.2014 | 02.02.2016 | Активен | 3213 | ||||
| J07CA02 | Diphteria, Tetanus, pertussis (acellular) and poliomyelitis (inactivated) vaccine (adsorbed) | ||||||||||||||||||||
| J07CA02 | diphtheria-pertussis-poliomyelitis-tetanus | TETRAXIM | Suspension for injection | 0,5 ml | 1 pre-filled syringe | Sanofi Pasteur S.A., Франция | mg | 19.28 | - | 19.28 | 100% | Z27.3 | КЦРР-999/23.07.2012 г.; HCР-284/28.06.2013; НСР-3015/12.03.2014 | 16.04.2014 | 8.9.2012. | 16.01.2014 | Активен | 2646 | |||
| J07CA02 | Diphteria, tetanus, pertussis and poliomyelitis vaccine | ||||||||||||||||||||
| J07CA02 | diphtheria-pertussis-poliomyelitis-tetanus | TETRAXIM | Suspension for injection | 0,5 ml | 1 pre-filled syringe 0,5 ml with 2 separate needles | Sanofi Pasteur S.A., Франция | - | 24.25 | - | 24.25 | 100% | Z27.3 | № 25/ 03.08.2009; КЦРР-2053/24.01.2013 г.; НСР-3262/14.04.2014 | 16.05.2014 | 08.09.2012 | 16.01.2014 | Активен | 2729 | |||
| J07CA02 | Diphteria, tetanus, pertussis (acellular, component) and Poliomyelitis (inactivated) vaccine (adsorbed) | ||||||||||||||||||||
| J07CA02 | diphtheria-pertussis-poliomyelitis-tetanus | Boostrix polio | Suspension for injection | 1 dose(0,5 ml) | 1 pre-filled syringe + 1 needle | ГлаксоСмитКлайн ЕООД, България | - | 42.06 | - | 42.06 | 100% | съгл. РУ | Z27.3 | КЦРР-1673/20.11.2012 г.; НСР-2753/17.02.2014; НСР-5459/16.01.2015 | 16.02.2015 | Активен | 3515 | ||||
| J07CA06 | Diphteria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and Haemophilis type b conjugate vaccine (adsorbed) | ||||||||||||||||||||
| J07CA06 | diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus | Infanrix-IPV+HIB | Powder and suspension for suspension for injection | 1 vial + 1 pre-filled syringe 0,5 ml + 2 needles | ГлаксоСмитКлайн ЕООД, България | mg | 45.91 | - | 45.91 | 100% | Z27.8 | № 44/07.01.2010 г.; № 57/05.03.2010 г.; КЦРР-2541/14.03.2013 г.; НСР-4994/05.11.2014; НСР-6674/09.07.2015; НСР-8326/26.02.2016 | 02.04.2016 | 08.09.2012 | Активен | 3339 | |||||
| J07CA06 | diphtheria-pertussis-poliomyelitis-tetanus | Pentaxim | Powder and solvent for suspension for injection | 1 vial powder, 1 pre-filled syringe 0.5ml for susp., 2 needles | Sanofi Pasteur S.A., Франция | - | 48.01 | - | 48.01 | 100% | Z27.8 | № 16/ 24.06.2009 г.; КЦРР-997/23.07.2012 | 08.09.2012 | 16.01.2014 | Активен | 1542 | |||||
| J07CA06 | diphtheria-pertussis-poliomyelitis-tetanus | Pentaxim | Powder and solvent for suspension for injection | 1 vial powder, 1 pre-filled syringe 0.5ml for susp. | Sanofi Pasteur S.A., Франция | - | 48.01 | - | 48.01 | 100% | Z27.8 | № 16/ 24.06.2009 г.; КЦРР-997/23.07.2012 | 08.09.2012 | 16.01.2014 | Активен | 1541 | |||||
| J07CA09 | Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) | ||||||||||||||||||||
| J07CA09 | diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B | Hexacima | Suspension for injection | 0,5 ml | 1 pre-filled syringe + 2 needles | Sanofi Pasteur S.A., Франция | 1 | dose | 72.01 | 72.01 | 72.01 | 100% | Z27.8 | НСР-3659/29.05.2014; НСР-4180/23.07.2014; НСР-4970/31.10.2014; НСР-5521/29.01.2015.; НСР-8627/31.03.2016. | 02.05.2016 | Активен | 3537 | ||||
| J07CA09 | diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B | Hexacima | Suspension for injection | 0,5 ml | 10 vials (glass) | Sanofi Pasteur S.A., Франция | 1 | dose | 1232.44 | 72.01 | 720.1 | 100% | Z27.8 | НСР-4954/27.10.2014; НСР-4970/31.10.2014 | 02.05.2016 | Активен | 3228 | ||||
| N02AA01 | Morphine | ||||||||||||||||||||
| N02AA01 | Morphine | Substitol | prolonged-release capsule, hard | 120 | mg | 30 | Mundipharma GmbH, Австрия | 100 | mg | 88.9 | 2.11333 | 76.08 | 100% | НСР-1378/07.10.2013 | 08.09.2012 | Активен | 636 | ||||
| N02AA01 | Morphine | Substitol | prolonged‐release capsule, hard | 200 | mg | 30 | Mundipharma GmbH, Австрия | 100 | mg | 126.8 | 2.11333 | 126.8 | 100% | НСР-1378/07.10.2013 | 08.09.2012 | Активен | 637 | ||||
| N07BC02 | Methadone | ||||||||||||||||||||
| N07BC02 | Methadone | METADON ALKALOID oral solution 10 mg/ml - 100 ml x 1 | Oral solution | 10 | mg/ml | 100 ml | Алкалоид ЕООД, България | 25 | mg | 10.5 | 0.262 | 10.48 | 100% | С възможност за закупуване от лечебни заведения, работещи по метадонови програми в рамките на държавната квота | 08.09.2012 | Активен | 102 | ||||
| N07BC02 | Methadone | METADON ALKALOID oral solution 10 mg/ml - 10 ml x 1 | Oral solution | 10 | mg/ml | 10 ml | Алкалоид ЕООД, България | 25 | mg | 1.76 | 0.2625 | 1.05 | 100% | HCР-390/03.07.2013 | 02.08.2013 | 08.09.2012 | Заличен | 101 | |||
| N07BC02 | Methadone | Methadone Sopharma oral solution 10 mg/ml - 100 ml x 1 | Oral solution | 10 | mg/ml | 100 ml | Софарма АД, България | 25 | mg | 10.48 | 0.262 | 10.48 | 100% | КЦРР-1892/15.12.2012 | 04.01.2013 | Активен | 1491 | ||||
| R07AA02 | Natural phospholipids | ||||||||||||||||||||
| R07AA02 | Natural phospholipids | CUROSURF | Endotracheopulmonary instillation, suspension | 80 mg/ ml - 1,5 ml | mg | 2 | Chiesi Farmaceutici SpA, Италия | 160 | mg | 1086.48 | 724.32001 | 1086.48 | 100% | P22.0 | 08.09.2012 | Активен | 454 | ||||
| V04CF01 | Tuberculini purified Protein Derivative for human use | ||||||||||||||||||||
| V04CF01 | Tuberculini purified Protein Derivative for human use | PPD Tuberculin Mammalian | Solution for injection | 5 TU/0.1 ml - 1 ml | x 10 флакони (10 дози) | БУЛ БИО-НЦЗПБ ЕООД, България | 5 | TU | 82.37 | 0.8237 | 82.37 | 100% | Z23.2 | НСР-9381/01.06.2016 | 02.07.2016 | Активен | 15138 | ||||
| V04CF01 | Tuberculini purified Protein Derivative for human use | PPD Tuberculin Mammalian | Solution for injection | 5 TU/0,1 ml | 1 fl. x 1 ml (10 doses) | БУЛ БИО-НЦЗПБ ЕООД, България | 5 | TU | 43.68 | 0.8237 | 8.24 | 100% | Z23.2 | № 209/ 04.11.2011 | 02.07.2016 | 08.09.2012 | Активен | 66 | |||
| V09AA01 | Technetium exametazime | ||||||||||||||||||||
| V09AA01 | Technetium [99mTc] exametazine | Ceretec | Kit for radiopharmaceutical preparation | 0,5mg | 5 | GE Healthcare Ltd, Обединено Кралство | 1 | mg | 1183.15 | 473.26 | 1183.15 | 100% | F03 | № 50/ 18.02.2010 | 08.09.2012 | Активен | 712 | ||||
| V09AB03 | Loflupane | ||||||||||||||||||||
| V09AB03 | Iodine Ioflupane (123I) | DATSCAN | Solution for injection | 74 MBq/ml-5 ml | 1 vial, glass | GE Healthcare Ltd, Обединено Кралство | 1 | ml | 1819.19 | 363.838 | 1819.19 | 100% | G20 | № 50/ 18.02.2010 | 08.09.2012 | Активен | 710 | ||||
| V09BA02 | Technetium medronic acid | ||||||||||||||||||||
| V09BA02 | Technetium (99Mtc) Medronic Acid | Amerscan Medronate II agent | Powder for solution for injection | 6,25 mg | mg | 5 | GE Healthcare Ltd, Обединено Кралство | mg | 211.31 | 6.76192 | 211.31 | 100% | C34.0,C34.1,C34.2,C34.3,C34.8,C34.9,C50.0,C50.1,C50.2,C50.3,C50.4,C50.5,C50.6,C50.8,C50.9,C61 | № 66/ 08.04.2010; № 123/13.12.2010; КЦРР-2050/24.01.2013 г.; НСР-4988/05.11.2014 | 02.12.2014 | 08.09.2012 | Заличен | 1744 | |||
| V09DB01 | Technetium nanocolloid | ||||||||||||||||||||
| V09DB01 | Technetium (99mTc) nanocolloid | Nanocoll | Powder for solution for injection | 0,5 mg/ vial | mg | 5 | GE Healthcare S.r.I., Италия | 1 | mg | 407.75 | 163.1 | 407.75 | 100% | C50.0,C50.1,C50.2,C50.3,C50.4,C50.5,C50.6,C50.8,C50.9,C61,C77.0,C77.3,C77.4,C77.8,C79.5 | № 50/ 18.02.2010; КП-40/05.03.2015 и НСР-3684/06.06.2014 | 08.09.2012 | Активен | 3654 | |||
| V09EB01 | Technetium macrosalb | ||||||||||||||||||||
| V09EB01 | Technetium (99mTc) macrosalb | Macrotec | Powder for suspension for injection | 2 mg/ vial | mg | 5 | GE Healthcare S.r.I., Италия | 1 | mg | 228.89 | 22.889 | 228.89 | 100% | I26.0,I26.9 | № 50/ 18.02.2010; НСР-6621/01.07.2015 | 08.09.2012 | Активен | 715 | |||
| V09FX01 | Mo sodium molybdate; Tc Technetium pertechnetate | ||||||||||||||||||||
| V09FX01 | Technetium (99mTc) pertechnetate | Drytec 2,5-100 GBq | Radionuclide generator | 15 GBq | 1 | GE Healthcare Ltd, Обединено Кралство | 1 | GBq | 1948.27 | 129.88467 | 1948.27 | 100% | №98/23.08.2010.; НСР-6672/09.07.2015 и НСР-6920/06.08.2015.; НСР-7501/13.11.2015 | 16.11.2015 | 08.09.2012 | Активен | 948 | ||||
| V09FX01 | Technetium (99mTc) pertechnetate | Drytec 2,5-100 GBq | Radionuclide generator | 12.5 GBq | 1 | GE Healthcare Ltd, Обединено Кралство | 1 | GBq | 1842.66 | 143.8456 | 1798.07 | 100% | №98/23.08.2010; №101/30.08.2010; НСР-7501/13.11.2015 | 08.09.2012 | Активен | 947 | |||||
| V09FX01 | Technetium (99mTc) pertechnetate | Drytec 2,5-100 GBq | Radionuclide generator | 10 GBq | 1 | GE Healthcare Ltd, Обединено Кралство | 1 | GBq | 1603.26 | 160.326 | 1603.26 | 100% | №98/23.08.2010; №101/30.08.2010.; НСР-6670/09.07.2015 и НСР-6918/06.08.2015.; НСР-7501/13.11.2015 | 16.11.2015 | 08.09.2012 | Активен | 946 | ||||
| V09FX01 | Technetium (99mTc) pertechnetate | Drytec 2,5-100 GBq | Radionuclide generator | 8.5 GBq | 1 | GE Healthcare Ltd, Обединено Кралство | 1 | GBq | 1612.66 | 189.72471 | 1612.66 | 100% | №98/23.08.2010; №101/30.08.2010; НСР-7501/13.11.2015 | 08.09.2012 | Активен | 945 | |||||
| V09FX01 | Technetium (99mTc) pertechnetate | Drytec 2,5-100 GBq | Radionuclide generator | 7.5 GBq | 1 | GE Healthcare Ltd, Обединено Кралство | 1 | GBq | 1399.08 | 186.544 | 1399.08 | 100% | №98/23.08.2010.; НСР-7177/09.10.2015.; НСР-7501/13.11.2015 | 16.11.2015 | 08.09.2012 | Активен | 944 | ||||
| V09FX01 | Technetium (99mTc) pertechnetate | Drytec 2,5-100 GBq | Radionuclide generator | 6 GBq | 1 | GE Healthcare Ltd, Обединено Кралство | 1 | GBq | 1255.91 | 209.31833 | 1255.91 | 100% | №98/23.08.2010.; НСР-7178/09.10.2015.; НСР-7501/13.11.2015 | 16.11.2015 | 08.09.2012 | Активен | 943 | ||||
| V09FX01 | Technetium (99mTc) pertechnetate | Drytec 2,5-100 GBq | Radionuclide generator | 5 GBq | 1 | GE Healthcare Ltd, Обединено Кралство | 1 | GBq | 1169.06 | 233.812 | 1169.06 | 100% | №98/23.08.2010; НСР-5953/01.04.2015.; НСР-7501/13.11.2015 | 16.11.2015 | 08.09.2012 | Активен | 3767 | ||||
| V09FX01 | Technetium (99mTc) pertechnetate | Drytec 2,5-100 GBq | Radionuclide generator | 4 GBq | 1 | GE Healthcare Ltd, Обединено Кралство | 1 | GBq | 1054.07 | 263.5175 | 1054.07 | 100% | №98/23.08.2010; НСР-5954/01.04.2015.; НСР-7501/13.11.2015 | 16.11.2015 | 08.09.2012 | Активен | 3766 | ||||
| V09FX01 | Technetium (99mTc) pertechnetate | Poltechnet 8,0 - 175 GBq | radionuclide generator | 12,5 GBq | GBq | 1 | National Centre for Nuclear Research, Полша, Полша | 1 | GBq | 1798.07 | 143.8456 | 1798.07 | 100% | НСР-7353/05.11.2015. и 7500/13.11.2015 | 16.11.2015 | Активен | 4104 | ||||
| V09FX01 | Technetium (99mTc) pertechnetate | Poltechnet 8,0 - 175 GBq | radionuclide generator | 7,5 GBq | GBq | 1 | National Centre for Nuclear Research, Полша, Полша | 1 | GBq | 1401.42 | 186.544 | 1399.08 | 100% | НСР-7353/05.11.2015. и 7500/13.11.2015 | 16.11.2015 | Активен | 4103 | ||||
| V09FX03; V10XA01 | Sodium iodide | ||||||||||||||||||||
| V09FX03,V10XA01 | Sodium iodide | Sodium Iodide [131 I] | Solution for injection | 3,7 GBq | 1 | GE Healthcare Buchler GmbH & Co., Германия | 1 | MBq | 500.78 | 0.13535 | 500.78 | 100% | C73 | № 50/ 18.02.2010.; НСР-7863/15.01.2016. | 02.03.2016 | 08.09.2012 | Активен | 701 | |||
| V09FX03,V10XA01 | Sodium iodide | Sodium Iodide [131 I] | Solution for injection | 1.85 GBq | 1 | GE Healthcare Buchler GmbH & Co., Германия | 1 | MBq | 301.15 | 0.16278 | 301.15 | 100% | C73 | № 50/ 18.02.2010.; НСР-7863/15.01.2016. | 02.03.2016 | 08.09.2012 | Активен | 700 | |||
| V09FX03,V10XA01 | Sodium iodide | Sodium Iodide [131 I] | Solution for injection | 740 MBq | 1 | GE Healthcare Buchler GmbH & Co., Германия | 1 | MBq | 175.87 | 0.23766 | 175.87 | 100% | C73 | № 50/ 18.02.2010.; НСР-7863/15.01.2016. | 02.03.2016 | 08.09.2012 | Активен | 702 | |||
| V09GA01 | Technetium (99mTc) Sestamibi | ||||||||||||||||||||
| V09GA01 | Technetium (99mTc) sestamibi | Technescan Sestamibi | Kit for radiopharmaceutical preparation | 1 mg | mg | 5 | Mallinkrodt Medical B.V., Нидерландия | 1 | mg | 1079.88 | 215.976 | 1079.88 | 100% | C34.0,C34.1,C34.2,C34.3,C34.8,C34.9,C50.0,C50.1,C50.2,C50.3,C50.4,C50.5,C50.6,C50.8,C50.9,C61,E21.0,E21.3,I20.1,I20.8,I20.9,I25.2,I25.5,I25.6,I25.8,I25.9 | № 70/ 19.04.2010; НСР-3682/06.06.2014 | 08.09.2012 | Активен | 2967 | |||
| V09GA02 | Technetium tetrofosmin | ||||||||||||||||||||
| V09GA02 | Technetium [99mTc] tetrofosmin | Myoview | Powder for solution for injection | 230 | mcg | 5 vial (kit for radiopharmaceutical preparation) | GE Healthcare Ltd, Обединено Кралство | 1 | mg | 1323.97 | 1151.27826 | 1323.97 | 100% | C34.0,C34.1,C34.2,C34.3,C34.8,C34.9,C50.0,C50.1,C50.2,C50.3,C50.4,C50.5,C50.6,C50.8,C50.9,C61,E21.0,E21.3,I20.1,I20.8,I20.9,I25.2,I25.5,I25.6,I25.8,I25.9 | № 50/ 18.02.2010 | 08.09.2012 | Активен | 711 | |||
| V09GX03 | Sodium chromate | ||||||||||||||||||||
| V09GX03 | Chromium (51Cr) Chromate Labelled Cells | Sodium chromate | Solution for injection | 37 MBq/ ml | GBq | 74 | GE Healthcare Ltd, Обединено Кралство | mg | 809.98 | 261.28387 | 809.98 | 100% | D69.6 | № 50/ 18.02.2010; НСР-4989/05.11.2014 | 08.09.2012 | Заличен | 714 | ||||
| V09GX03 | Chromium (51Cr) Chromate Labelled Cells | Sodium chromate | Solution for injection | 37 MBq/ ml | GBq | 37 | GE Healthcare Ltd, Обединено Кралство | mg | 511.91 | 165.13226 | 511.91 | 100% | D69.6 | № 50/ 18.02.2010; НСР-4989/05.11.2014 | 08.09.2012 | Заличен | 713 | ||||
| V09IX02 | Iobenguane | ||||||||||||||||||||
| V09IX02 | Iobenguane (131 I) | [131 I] Meta-iodobenzylguanidine for diagnostic use | Solution for injection | 37 MBq/1ml | 1 | GE Healthcare Buchler GmbH & Co., Германия | 1 | ml | 540.07 | 540.07 | 540.07 | 100% | C74.1,C74.9,C75.9,D35.0 | № 50/ 18.02.2010 | 08.09.2012 | Активен | 704 | ||||
| V10BX01 | Strontium chloride | ||||||||||||||||||||
| V10BX01 | Strontium (89 Sr) chloride | Metastron | Solution for injection | 150 MBq - 4 ml | MBq | 1 | GE Healthcare Ltd, Обединено Кралство | 1 | MBq | 1860.22 | 12.40147 | 1860.22 | 100% | C34.0,C34.1,C34.2,C34.3,C34.8,C34.9,C50.0,C50.1,C50.2,C50.3,C50.4,C50.5,C50.6,C50.8,C50.9,C61 | №98/23.08.2010; НСР-4656/25.09.2014. и КП-97/06.04.2015; КП-315/17.06.2015 и НСР-5952/01.04.2015 | 16.07.2015 | 08.09.2012 | Активен | 3786 | ||
| V10XA01 | Sodium Iodide | ||||||||||||||||||||
| V10XA01 | Sodium iodide | Theracap 131 | Capsule, hard | 3,7 GBq | 1 | GE Healthcare Buchler GmbH & Co., Германия | 1 | MBq | 575.28 | 0.15548 | 575.28 | 100% | C73 | № 50/ 18.02.2010 | 02.03.2016 | 08.09.2012 | Активен | 703 | |||
| V10XA01 | Sodium iodide | Theracap 131 | Capsule, hard | 1850 MBq | 1 | GE Healthcare Buchler GmbH & Co., Германия | 1 | MBq | 279.48 | 0.15107 | 279.48 | 100% | C73 | № 50/ 18.02.2010; НСР-6617/01.07.2015 | 02.03.2016 | 08.09.2012 | Активен | 709 | |||
| V10XA01 | Sodium iodide | Theracap 131 | Capsule, hard | 370 MBq | 1 | GE Healthcare Buchler GmbH & Co., Германия | 1 | MBq | 129.07 | 0.34884 | 129.07 | 100% | C73 | № 50/ 18.02.2010; НСР-6619/01.07.2015 | 02.03.2016 | 08.09.2012 | Активен | 707 | |||
| V10XA01 | Sodium iodide | Theracap 131 | Capsule, hard | 185 MBq | 1 | GE Healthcare Buchler GmbH & Co., Германия | 1 | MBq | 118.06 | 0.63816 | 118.06 | 100% | C73 | № 50/ 18.02.2010; НСР-6620/01.07.2015 | 02.03.2016 | 08.09.2012 | Активен | 706 | |||
| V10XA01 | Sodium iodide | Theracap 131 | Capsule, hard | 74 MBq | 1 | GE Healthcare Buchler GmbH & Co., Германия | 1 | MBq | 288.02 | 3.89216 | 288.02 | 100% | C73 | № 50/ 18.02.2010.; НСР-8091/12.02.2016 и НСР-7865/15.01.2016. | 02.03.2016 | 08.09.2012 | Активен | 705 |